NEB and Touchlight Launch Cell-Free DNA Synthesis Kit to Disrupt Therapeutic Development
Event summary
- New England Biolabs (NEB) released the EnClose Cell-free dbDNA Synthesis Kit on March 18, 2026, in collaboration with Touchlight.
- The kit enables benchtop enzymatic synthesis of Touchlight's proprietary doggybone DNA (dbDNA), a linear, covalently closed, double-stranded DNA.
- The technology bypasses traditional plasmid DNA manufacturing, reducing development timelines for mRNA vaccines and gene therapies by months.
- dbDNA is free of bacterial sequences and antibiotic resistance genes, simplifying regulatory compliance and enhancing safety.
- The kit is scalable from research to production, ideal for viral vector manufacturing and nucleic acid therapeutics.
The big picture
The launch of the EnClose kit addresses a critical bottleneck in nucleic acid therapeutic development, offering a faster, safer alternative to traditional plasmid DNA. This collaboration aligns with the broader industry shift toward scalable, cell-free manufacturing solutions, potentially reshaping the landscape for mRNA vaccines and gene therapies. The technology's ability to synthesize difficult sequences could further expand its applications in viral vector manufacturing and non-viral gene therapy.
What we're watching
- Adoption Pace
- How quickly researchers and developers will integrate the EnClose kit into their workflows, potentially accelerating therapeutic timelines.
- Regulatory Advantage
- Whether the kit's bacterial-free DNA will streamline regulatory approvals for nucleic acid therapeutics.
- Market Expansion
- The pace at which NEB and Touchlight can scale production to meet growing demand for cell-free DNA synthesis solutions.
Related topics